Published in Hepatitis Weekly, February 24th, 2003
According to Yehuda Z. Patt and colleagues, cirrhosis is often seen in patients diagnosed with hepatocellular carcinoma (HCC), but its presence also means that certain chemotherapies can not be used. FU and IFN-alfa-2b may be appropriate for treating those patients, based on the results of a phase II clinical trial.
For the trial, physicians prescribed continuous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.